Profile of pembrolizumab in the treatment of head and neck squamous cell carcinoma: design development and place in therapy

Sulsal Haque(Palmetto Hematology Oncology), Nooshin Hashemi-Sadraei(Palmetto Hematology Oncology)
Drug Design Development and Therapy
August 1, 2017
10.2147/dddt.s119537
Cited by 7

Related Papers

Phase II Trial of Adjuvant Nivolumab Following Salvage Resection in Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck
|Clinical Cancer Research|2022|26
Adjuvant nivolumab following salvage resection in head and neck squamous cell carcinoma patients previously treated with definitive therapy: A single-arm phase II multi-institutional study.
|Journal of Clinical Oncology|2021|5
Data from Phase II Trial of Adjuvant Nivolumab Following Salvage Resection in Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck
|Unknown|2023|1
Supplementary Table from Phase II Trial of Adjuvant Nivolumab Following Salvage Resection in Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck
|Unknown|2023|0
Supplementary Table from Phase II Trial of Adjuvant Nivolumab Following Salvage Resection in Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck
|Unknown|2023|0